94 related articles for article (PubMed ID: 17071167)
1. Long-term outcome of HBV carriers with negative HBe antigen and normal aminotransferase.
Ikeda K; Arase Y; Saitoh S; Kobayashi M; Someya T; Hosaka T; Sezaki H; Akuta N; Suzuki Y; Suzuki F; Kumada H
Am J Med; 2006 Nov; 119(11):977-85. PubMed ID: 17071167
[TBL] [Abstract][Full Text] [Related]
2. Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death.
Chen JD; Yang HI; Iloeje UH; You SL; Lu SN; Wang LY; Su J; Sun CA; Liaw YF; Chen CJ;
Gastroenterology; 2010 May; 138(5):1747-54. PubMed ID: 20114048
[TBL] [Abstract][Full Text] [Related]
3. Prophylactic lamivudine administration prevents exacerbation of liver damage in HBe antigen positive patients with hepatocellular carcinoma undergoing transhepatic arterial infusion chemotherapy.
Nagamatsu H; Itano S; Nagaoka S; Akiyoshi J; Matsugaki S; Kurogi J; Tajiri N; Yamasaki S; Koga H; Torimura T; Kumashiro R; Sata M
Am J Gastroenterol; 2004 Dec; 99(12):2369-75. PubMed ID: 15571585
[TBL] [Abstract][Full Text] [Related]
4. Occult hepatitis B virus infection increases hepatocellular carcinogenesis by eight times in patients with non-B, non-C liver cirrhosis: a cohort study.
Ikeda K; Kobayashi M; Someya T; Saitoh S; Hosaka T; Akuta N; Suzuki F; Suzuki Y; Arase Y; Kumada H
J Viral Hepat; 2009 Jun; 16(6):437-43. PubMed ID: 19226331
[TBL] [Abstract][Full Text] [Related]
5. Viral level is an indicator of long-term outcome of hepatitis B virus e antigen-negative carriers with persistently normal serum alanine aminotransferase levels.
Nakazawa T; Shibuya A; Takeuchi A; Shibata Y; Hidaka H; Okuwaki Y; Takada J; Tanaka Y; Watanabe M; Minamino T; Sakurai K; Koizumi W
J Viral Hepat; 2011 Jul; 18(7):e191-9. PubMed ID: 21692932
[TBL] [Abstract][Full Text] [Related]
6. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus.
Adachi S; Shibuya A; Miura Y; Takeuchi A; Nakazawa T; Saigenji K
Scand J Gastroenterol; 2008; 43(7):849-56. PubMed ID: 18584524
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with the intensity of liver fibrosis in renal transplant patients with hepatitis B virus infection.
Matos CA; Perez RM; Lemos LB; Medina-Pestana JO; Lanzoni VP; Alberto FL; Moreira ES; Silva AE; Ferraz ML
Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):653-7. PubMed ID: 17625434
[TBL] [Abstract][Full Text] [Related]
8. Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels.
Chu CM; Hung SJ; Lin J; Tai DI; Liaw YF
Am J Med; 2004 Jun; 116(12):829-34. PubMed ID: 15178498
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of HBV DNA load in patients with chronic hepatitis B infection.
Madan K; Batra Y; Jha JK; Kumar S; Kalra N; Paul SB; Singh R; Duttagupta S; Panda SK; Acharya SK
Trop Gastroenterol; 2008; 29(2):84-90. PubMed ID: 18972767
[TBL] [Abstract][Full Text] [Related]
10. Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma.
Tsai FC; Liu CJ; Chen CL; Chen PJ; Lai MY; Kao JH; Chen DS
J Viral Hepat; 2007 Mar; 14(3):153-60. PubMed ID: 17305880
[TBL] [Abstract][Full Text] [Related]
11. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.
Chen CF; Lee WC; Yang HI; Chang HC; Jen CL; Iloeje UH; Su J; Hsiao CK; Wang LY; You SL; Lu SN; Chen CJ;
Gastroenterology; 2011 Oct; 141(4):1240-8, 1248.e1-2. PubMed ID: 21703214
[TBL] [Abstract][Full Text] [Related]
12. Significance of hepatitis B virus DNA clearance and early prediction of hepatocellular carcinogenesis in patients with cirrhosis undergoing interferon therapy: long-term follow up of a pilot study.
Ikeda K; Kobayashi M; Saitoh S; Someya T; Hosaka T; Akuta N; Suzuki Y; Suzuki F; Tsubota A; Arase Y; Kumada H
J Gastroenterol Hepatol; 2005 Jan; 20(1):95-102. PubMed ID: 15610453
[TBL] [Abstract][Full Text] [Related]
13. Pre-S deletion and complex mutations of hepatitis B virus related to advanced liver disease in HBeAg-negative patients.
Chen CH; Hung CH; Lee CM; Hu TH; Wang JH; Wang JC; Lu SN; Changchien CS
Gastroenterology; 2007 Nov; 133(5):1466-74. PubMed ID: 17915220
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study.
Fwu CW; Chien YC; Kirk GD; Nelson KE; You SL; Kuo HS; Feinleib M; Chen CJ
J Natl Cancer Inst; 2009 Jul; 101(14):1019-27. PubMed ID: 19535774
[TBL] [Abstract][Full Text] [Related]
15. Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus.
Chu CM; Liaw YF
Am J Gastroenterol; 2009 Jul; 104(7):1693-9. PubMed ID: 19455130
[TBL] [Abstract][Full Text] [Related]
16. Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area.
Yin J; Zhang H; Li C; Gao C; He Y; Zhai Y; Zhang P; Xu L; Tan X; Chen J; Cheng S; Schaefer S; Cao G
Carcinogenesis; 2008 Sep; 29(9):1685-91. PubMed ID: 18192693
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis B virus DNA in liver tissue and risk for hepatocarcinogenesis in patients with hepatitis C virus-related chronic liver disease. A prospective study.
Obika M; Shinji T; Fujioka S; Terada R; Ryuko H; Lwin AA; Shiraha H; Koide N
Intervirology; 2008; 51(1):59-68. PubMed ID: 18349544
[TBL] [Abstract][Full Text] [Related]
18. Positive serum hepatitis B e antigen is associated with higher risk of early recurrence and poorer survival in patients after curative resection of hepatitis B-related hepatocellular carcinoma.
Sun HC; Zhang W; Qin LX; Zhang BH; Ye QH; Wang L; Ren N; Zhuang PY; Zhu XD; Fan J; Tang ZY
J Hepatol; 2007 Nov; 47(5):684-90. PubMed ID: 17854945
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients.
Kumar M; Chauhan R; Gupta N; Hissar S; Sakhuja P; Sarin SK
Gastroenterology; 2009 Apr; 136(4):1272-80. PubMed ID: 19208347
[TBL] [Abstract][Full Text] [Related]
20. Two-year lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B: a double-blind, placebo-controlled trial.
Chan HL; Wang H; Niu J; Chim AM; Sung JJ
Antivir Ther; 2007; 12(3):345-53. PubMed ID: 17591024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
